JGK-263
JGK-263 is an orally active Glycogen synthase kinase-3β (GSK-3β) inhibitor. JGK-263 exhibits neuroprotective effect and can improve motor function. JGK-263 can be used for the research of neurological disease, such as amyotrophic lateral sclerosis (ALS) [1].
Product Specifications
CAS Number
1408054-46-5
UNSPSC
12352005
Target
GSK-3
Related Pathways
PI3K/Akt/mTOR; Stem Cell/Wnt
Field of Research
Neurological Disease
Smiles
O=C1NN=C2C(NCCCC3=CC=NC=C3)=CC(Cl)=CN21
Molecular Formula
C14H14ClN5O
Molecular Weight
303.75
References & Citations
[1]Ahn SW, et al. Neuroprotective effects of JGK-263 in transgenic SOD1-G93A mice of amyotrophic lateral sclerosis. J Neurol Sci. 2014 May 15;340 (1-2) :112-6.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
GSK-3β
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC402853-500 1x 500 µL
CD54 / ICAM-1 (15.2), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400158-500 1x 500 µL
Cytokeratin 17 (E3), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC801037-500 1x 500 µL
CD44 Standard (DF1485), CF680 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC682216-100 1x 100 µL
CD50 / ICAM3 (CG106), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 